Teresa Hong

Teresa Hong

Auto-generated profile, based on publicly available information

Teresa Hong

Department of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Eric Chekwube AniogoEric Chekwube Aniogo
Eric Chekwube Aniogo
LWLindsay Williams
Lindsay Williams
THTeresa Hong
Teresa Hong
PWPatty Wong
Patty Wong
SHSusanta Hui
Susanta Hui
MKMaciej Kujawski
Maciej Kujawski
Background/Objectives: Immunocytokines (ICKs) are antibody–cytokine fusion proteins that deliver cytokines directly to tumors to increase immune responses, which are otherwise absent or limited by the delivery of antibodies alone. Tumor-associated glycoprotein-72 (TAG72) is overexpressed in numerous solid tumors. Methods: An anti-TAG72-IL-2 fusion protein was expressed in mammalian cells and tested in vitro for binding and bioactivity, and in vivo in two models. Results: In vitro studies showed high antigen specificity against TAG-72-positive tumor cell lines and IL-2 activity in CD25 (IL-2R)-positive reporter cells. To study the anti-tumor activity of huCC49-IL-2 in an immunocompetent model, the TAG-72 expression was established in murine mammary and colorectal cells by transfection with murine st6galnac-I gene (mSTn). Four daily doses of anti-TAG72-IL-2 monotherapy for TAG-72-expressing orthotopic murine mammary tumors in immunocompetent mice resulted in minimal whole-body toxicity and significant tumor growth reduction mediated by tumor infiltration of IFNγ+ CD8+ T cells. When mammary tumors were pretreated with image-guided fractionated radiation therapy (IGRT) followed by anti-TAG72-IL-2 therapy, an improved tumor growth inhibition was observed along with an increased tumor infiltration of IFNγ+ CD8+ T cells and a significant reduction in Foxp3+ CD4+ cells. Anti-TAG72-IL-2 monotherapy in TAG-72+ colorectal tumors led to a significant tumor reduction but also cures (4/7), with a rejection of rechallenges with both TAG-72-positive and -negative MC38 cells, thus demonstrating evidence of immune memory and antigen spreading. Conclusions: antiTAG-72-IL-2 therapy showed strong anti-tumor effects driven by activated CD8+ T cells making it a promising approach to the treatment of TAG-72+ tumors.